Study
The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults (ATLAS 2)
A confirmatory trial testing whether urolithin A (Mitopure) at 500 mg and 1000 mg improves muscle strength in healthy 40-65 year olds over six months, following up on the 2022 Singh trial.
Summary Does urolithin A improve muscle strength in healthy middle-aged adults? Show / hide ↓
Researchers plan to study whether daily urolithin A improves muscle strength over six months. About three groups will take either a dummy pill, 500 milligrams, or 1,000 milligrams of urolithin A. The study will include healthy adults aged 40 to 65 with BMI, a weight-to-height measure, between 25 and 34.9 and low activity levels. People will be assigned by chance, and neither participants nor researchers will know who receives the real supplement until the study ends. Strength, health, and physical performance will be checked at the start, after four months, and after six months, but results are not available yet.
What this means for you: This study does not provide evidence you can use yet because it has not finished. There is no strong reason to buy urolithin A for muscle strength until this trial and other studies confirm a benefit.
early evidenceThis is a trial registration, not a completed study. ATLAS 2 (sponsor Amazentis, run through Atlantia Clinical Trials in Cork, Ireland) enrolls healthy adults aged 40 to 65 with BMI 25-34.9 and low physical activity levels. Participants take placebo, 500 mg, or 1000 mg Mitopure daily for six months. The trial measures muscle strength, health, and performance at baseline, four months, and six months. It exists to confirm the muscle-strength signal from the 2022 Singh et al. trial (NCT03464500), which found roughly 12 percent hamstring strength improvement at 500 mg. Recruitment window is December 2025 to April 2027, with last-participant-last-visit expected October 2027. No results exist yet. The value of this entry is tracking status: this is the study that would either confirm or fail to replicate urolithin A's strongest human signal in the longevity supplement category. Until it reads out, urolithin A's evidence base rests on a single trial and its substudies.
n/a - trial has not completed or reported results
Registration only. No data yet. Recruiting status as of the source date. Confirmatory trial design implies the sponsor considers the original 2022 result strong enough to warrant a larger replication, but replication outcomes are unknown until 2027.
Cited by
1 encyclopedia entries reference this study.